New Drug Treats Rheumatoid Arthritis

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 113, Nº. 3, 2013, págs. 22-23
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Tofacitinib (Xeljanz) has been approved to treat moderate-to-severe rheumatoid arthritis in adults who've had an inadequate response to or cannot tolerate methotrexate.

    * The drug can produce serious, even life-threatening, infections. The most common serious infections reported include pneumonia, cellulitis, herpes zoster, and urinary tract infection. Tuberculosis and other opportunistic infections are also possible.

    * Tofacitinib can decrease various cell counts, and blood counts need to be assessed carefully before and during therapy.